Does Viloxazine Really Improve Sex Drive? A Double-Blind Controlled Study

1986 ◽  
Vol 148 (5) ◽  
pp. 597-599 ◽  
Author(s):  
Diego De Leo ◽  
Guido Magni
Keyword(s):  
Ad Hoc ◽  
Depression Scale ◽  
Expression Level ◽  
Controlled Study ◽  
Double Blind Trial ◽  
Trial Period ◽  
Double Blind ◽  
Blind Trial ◽  
Sex Drive ◽  
Randomised Controlled

The action of viloxazine on libido and sex drive was evaluated with a randomised controlled double-blind trial against placebo on a population of 26 male out-patients affected by primary depression (DSM III). Modifications in the sexual sphere were assessed by the ad hoc inclusion of a series of items in the Zung Self-Rating Depression Scale. Thus modified, the scale was administered at the beginning and the end of a four-week trial period. Viloxazine proved to have a considerable disinhibiting effect, whose principal expression level was a return to pre-depression levels of frequency in sexual relations.

A Double-Blind Trial of Penbutolol: A New Beta-Receptor Blocking Agent in the Treatment of Angina Pectoris

1976 ◽  
Vol 4 (6) ◽  
pp. 410-417 ◽  
Author(s):  
A K Agarwal ◽  
R C Ahuja ◽  
M Chandra ◽  
N N Gupta ◽  
M Hasan
Keyword(s):  
Angina Pectoris ◽  
Blocking Agent ◽  
Controlled Study ◽  
Double Blind Trial ◽  
Subjective Improvement ◽  
Double Blind ◽  
Dosage Range ◽  
Double Blind Placebo ◽  
Receptor Blocking ◽  
Blind Trial

A double-blind placebo controlled study of angina pectoris with Penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for Penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the Penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.

Oral Buflomedil in Diabetic Background Retinopathy: Results of a Preliminary Controlled Study

1984 ◽  
Vol 12 (3) ◽  
pp. 184-187 ◽  
Author(s):  
N Ducrey ◽  
B Curchod
Keyword(s):  
Placebo Group ◽  
Controlled Study ◽  
Diabetic Patients ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Background Retinopathy ◽  
Number Of Patients ◽  
Insulin Dependent ◽  
Insulin Dependent Diabetic

Twenty insulin-dependent diabetic patients with signs of background retinopathy were given Buflomedil 600 mg/day orally or placebo in a randomized double-blind trial for a 6-month period. A larger number of patients had their retinal condition deteriorating in the placebo group and this finding is an indication for pursuing investigations on a larger scale in this direction.

A Double-Blind Trial: Vivalan against Placebo in Depressed Elderly Patients

1980 ◽  
Vol 8 (1) ◽  
pp. 18-21 ◽  
Author(s):  
L Knorring Von
Keyword(s):  
Elderly Patients ◽  
Cardiac Disease ◽  
Depressive Illness ◽  
Primary Diagnosis ◽  
Controlled Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Depressed Patients ◽  
Depression Ratings

A double-blind controlled study of viloxazine against placebo in elderly depressed patients with a primary diagnosis of depressive illness records statistically significant improvements in depression ratings in the viloxazine group after three weeks. Viloxazine was effective and well tolerated at doses of 100 to 200 mg in depressed elderly patients, several of whom had concurrent cardiac disease.

Sign in / Sign up

Export Citation Format

Share Document